(Health-NewsWire.Net, December 11, 2018 ) Some of the major market players in breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US),Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).
Access Free Sample Brochure of Breast Cancer Liquid Biopsy Market spread across 82 Pages, Profiling Few Companies and Supported with 15 Tables and 11 Figures is now available at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1611705 .
The global breast cancer liquid biopsy market is estimated to grow at a CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach USD 411.1 million by 2022. Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.
Liquid Biopsy Market, by Circulating Biomarker Circulating Tumor Cells (CTCs) Cell-free DNA (cfDNA) Extracellular Vesicles (EVs) Circulating Biomarkers
Liquid Biopsy Market, by End User Reference Laboratories Hospitals and Physician Laboratories Other End Users
Get 15% Discount Now on Breast Cancer Liquid Biopsy Market Now at http://www.rnrmarketresearch.com/contacts/discount?rname=1611705 .
North America is expected to account for the largest share of the global breast cancer liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of breast cancer, and improving healthcare infrastructure are driving the growth of breast cancer liquid biopsy market in this region.
Target Audience: Liquid biopsy system manufacturers, suppliers, and distributors Research institutes Physicians and surgeons Healthcare service providers and clinical research organizations Market research and consulting firms
Click here for Place the Order and More Information Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022 report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=1611705 .
Objectives of the Study To define, describe, and forecast the breast liquid biopsy market on the basis of circulating biomarkers, end user, and region To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges) To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World To profile key players and comprehensively analyze their market shares and core competencies To track and analyze the competitive technology, investments, funding for the breast cancer liquid biopsy market To track and analyze competitive developments such as acquisitions, product developments, partnerships, agreements, expansions, and collaborations in the liquid biopsy market
ReportsnReports
Vishal
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com
|